Trial Enrollment Progress Advances Voro Urologic Scaffold Evaluation

According to a recent LinkedIn post from Levee Medical, Academic Urology and Urogynecology of Arizona has enrolled its first patient in the ARID II IDE pivotal trial, making it the 16th site to do so. The post notes that the study is evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence following prostate surgery.

The post suggests that continued site activation and patient enrollment in ARID II could be an important step toward generating the clinical evidence needed for potential regulatory review and future commercialization. For investors, successful progression of this pivotal trial may influence Levee Medical’s valuation prospects, competitive positioning in post-prostatectomy care, and the timing of any eventual market entry for the Voro device.